TipRanks
Innate Pharma (IPHA)
NASDAQ:IPHA
US Market
IPHA
Innate Pharma
RESEARCH TOOLSreports
Want to see IPHA full AI Analyst Report?

Innate Pharma (IPHA) Stock News & Sentiment

148 Followers
Innate Pharma: Buy Rating Reaffirmed on Pipeline Momentum and De‑Risking Catalysts; $8 Price Target Unchanged
Premium
Ratings
Innate Pharma: Buy Rating Reaffirmed on Pipeline Momentum and De‑Risking Catalysts; $8 Price Target Unchanged
4M ago
IPHA
Innate Pharma: Underappreciated Topo‑I ADC Pipeline and Differentiated IPH4502 Support Buy Rating
Premium
Ratings
Innate Pharma: Underappreciated Topo‑I ADC Pipeline and Differentiated IPH4502 Support Buy Rating
5M ago
IPHA
Innate Pharma: Diversified Oncology Pipeline and AstraZeneca Partnership Create Compelling Upside Ahead of 2026 Inflection Points
Premium
Ratings
Innate Pharma: Diversified Oncology Pipeline and AstraZeneca Partnership Create Compelling Upside Ahead of 2026 Inflection Points
6M ago
IPHA
Innate Pharma SA Reports First Half 2025 Financial Results
Premium
Company Announcements
Innate Pharma SA Reports First Half 2025 Financial Results
12M ago
IPHA
Innate Pharma’s Strategic Shift and Financial Challenges Lead to Hold Rating
Premium
Ratings
Innate Pharma’s Strategic Shift and Financial Challenges Lead to Hold Rating
12M ago
IPHA
Premium
Company Announcements
Innate Pharma’s IPH4502 Study: A New Hope in Cancer Treatment
1y ago
IPHA
Innate Pharma: Navigating Challenges with Promising Pipeline and Strategic Partnerships
Premium
Ratings
Innate Pharma: Navigating Challenges with Promising Pipeline and Strategic Partnerships
1y ago
IPHA
More IPHA News >

IPHA News on the Web

Half Year 2026 Innate Pharma SA Earnings Call Transcript
GuruFocus News
Neutral
Analysts Offer Insights on Healthcare Companies: Guardant Health (GH), NRX Pharmaceuticals (NRXP) and Innate Pharma (IPHA)
TipRanks News
Bullish
Innate Pharma SA To Hold Conference Call Transcript
GuruFocus News
Neutral
Innate Pharma CMO Sonia Quaratino to depart, Markus Jensen to succeed
TipRanks News
Bullish
Innate Pharma, Sobi to enable initiation of the TELLOMAK-3 study
TipRanks News
Bullish
Innate Pharma completes enrollment in dose escalation of IPH4502 study
TipRanks News
Bullish
H.C. Wainwright Sticks to Their Buy Rating for Innate Pharma (IPHA)
TipRanks News
Bullish
Innate Pharma: Buy Rating Reaffirmed on Pipeline Momentum and De‑Risking Catalysts; $8 Price Target Unchanged
TipRanks News
Bullish

News Score - Last 7 Days

Neutral
IPHA
Sector Average
Media Buzz
This Week1 articles
Weekly Average1 articles
News Sentiment
This Week100%
Sector Average91%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is IPHA’s Media Buzz Sentiment?
1 articles about IPHA were published this week. In an average week, 1 articles are published.
    What is IPHA’s weekly average amount of articles?
    In an average week, 1 articles about IPHA are published.
      What is IPHA’s News Sentiment?
      100% of articles about IPHA were positive this week, compared to its sector average of 91%.
        Healthcare Stocks that are Trending in the News
        VCYTVeracyte
        BMYBristol-Myers Squibb
        SLDBSolid Biosciences
        DFTXDefinium Therapeutics
        LHLabcorp Holdings
        Showing the stocks with the most bullish news sentiment over the past week